
    
      This is a single-arm, phase 1b study to determine the maximum tolerated dose (MTD) of the
      combination of erlotinib (daily), gemcitabine (weekly), nab-paclitaxel (weekly) in patients
      with advanced pancreatic cancer.
    
  